Sight Sciences Uses RWE To Refine Patient Segmentation And Reverse A Medicare Ruling For OMNI

Sight Sciences faced a critical challenge when Medicare issued a Limited Coverage Determination (LCD) that threatened their attempts to utilize OMNI^® Surgical System as a glaucoma treatment option. Given glaucoma’s prevalence among older adults—most of whom are covered by Medicare—and limitations of internal studies that didn’t reflect real-world variability, the company needed robust, real-world evidence to support OMNI’s clinical value when treating glaucoma. To address this, Sight Sciences partnered with Verana Health to analyze a dataset of 100,000 patients from the largest eye disease clinical registry, linked with claims data.

This assistance allowed for a nuanced evaluation of OMNI across patient subgroups, including severity levels and underserved populations such as African Americans with late-stage diagnoses. The analysis revealed that OMNI was widely used by diverse physicians in real-world practice for severe glaucoma cases. These insights demonstrated the device’s clinical relevance and equity in care delivery, directly contributing to Medicare’s reversal of the LCD. This partnership not only preserved access to a key treatment but also safeguarded Sight Sciences’ core revenue stream by validating OMNI’s value through high-quality real-world data.